Swedish Orphan Biovitrum AB (Sobi) says it has earmarked international expansion as a key priority after a busy 2020 which saw its late-stage R&D pipeline grow through partnerships with two US biotechs, Selecta Biosciences, Inc. and Apellis Pharmaceuticals, Inc. and the approval extension for the thrombopoietin receptor agonist Doptelet (avatrombopag) in early 2021 in the EU.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?